Meeting
2021 ASCO Annual Meeting
Impact of pharmacodynamic biomarkers in immuno-oncology (IO) phase 1 clinical trials.
Authors
Abdulazeez Salawu
Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, Canada
Abdulazeez Salawu , Rachel Chen , Alberto Hernando-Calvo , Daniel Vilarim Araujo , Marc Oliva Bernal , Zhihui (Amy) Liu , Lillian L. Siu
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Immunotherapy
Track
Developmental Therapeutics—Immunotherapy
Sub Track
Other IO-Related Topics
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 2653)
DOI
10.1200/JCO.2021.39.15_suppl.2653
Abstract #
2653
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
First-in-human, phase I study of PF-06753512, a vaccine-based immunotherapy regimen (PrCa VBIR), in biochemical relapse (BCR) and metastatic castration-resistant prostate cancer (mCRPC).
First Author: Karen A. Autio
Poster
2017 ASCO Annual Meeting
A phase 1 study to evaluate the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of the OX40 agonist MEDI0562 in combination with tremelimumab or durvalumab in adult aubjects with advanced solid tumors.
First Author: Brendan D. Curti
Poster
2024 ASCO Annual Meeting
High dose bolus (HDB) interleukin-2 (IL2) and concurrent low dose ipilimumab followed sequentially by nivolumab in patients with advanced melanoma after failure of anti-PD1-based immunotherapy and BRAF-MEK inhibition.
First Author: Ahmad A. Tarhini
Poster
2024 ASCO Annual Meeting
Pan-cancer B- and T-cell transcriptome analysis of CXCL13 as a predictive marker for immune checkpoint inhibitor response.
First Author: Yu Fujiwara